The role of diabetes co-morbidity for tuberculosis treatment outcomes:a prospective cohort study from Mwanza, Tanzania by Faurholt-Jepsen, Daniel et al.
RESEARCH ARTICLE Open Access
The role of diabetes co-morbidity for tuberculosis
treatment outcomes: a prospective cohort study
from Mwanza, Tanzania
Daniel Faurholt-Jepsen1*, Nyagosya Range2, George Praygod3, Jeremiah Kidola3, Maria Faurholt-Jepsen1,
Martine Grosos Aabye4, John Changalucha3, Dirk Lund Christensen5,6, Torben Martinussen7, Henrik Krarup8,
Daniel Rinse Witte6, Åse Bengård Andersen9 and Henrik Friis1
Abstract
Background: Due to the association between diabetes and pulmonary tuberculosis (TB), diabetes may threaten the
control of TB. In a prospective cohort study nested in a nutrition trial, we investigated the role of diabetes on
changes in anthropometry, grip strength, and clinical parameters over a five months follow-up period.
Methods: Among pulmonary TB patients with known diabetes status, we assessed anthropometry and clinical
parameters (e.g. haemoglobin) at baseline and after two and five months of TB treatment. A linear mixed-effects
model (repeated measurements) was used to investigate the role of diabetes during recovery.
Results: Of 1205 TB patients, the mean (standard deviation) age was 36.6 (13.0) years, 40.9% were females, 48.9%
were HIV co-infected, and 16.3% had diabetes. TB patients with diabetes co-morbidity experienced a lower weight
gain at two (1.3 kg, CI95% 0.5; 2.0, p = 0.001) and five months (1.0 kg, CI95% 0.3; 1.7, p = 0.007). Similarly, the increase
in the level of haemoglobin was lower among TB patients with diabetes co-morbidity after two (Δ 0.6 g/dL, CI95%
0.3; 0.9 p< 0.001) and five months (Δ 0.5 g/dL, CI95% 0.2; 0.9 p = 0.004) of TB treatment, respectively.
Conclusion: TB patients initiating TB treatment with diabetes co-morbidity experience delayed recovery of body
mass and haemoglobin, which are important for the functional recovery from disease.
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Background
Chronic and infectious diseases often co-exist due to
mutual risk factors as well as direct interactions between
the diseases. One of the major challenges is the double
burden of diabetes and pulmonary tuberculosis (TB) [1].
With the on-going diabetes epidemic in low-income
countries already burdened by TB [2], diabetes may
threaten the control of TB.
Previous studies have found that diabetes may impair
sputum conversion and cure [3-5] and increase the risk
of relapse [6]. However, the studies focus on the treat-
ment outcome related to clearance of the TB bacteria
and do not take into account the impact of diabetes on
the outcome of other factors such as body composition,
functional recovery, as well as other clinical parameters
affected by disease. We have previously demonstrated a
10 kg weight deficit among newly diagnosed TB patients
compared to non-TB individuals [7], thus the regain of
lean and fat mass is an important part of TB recovery,
since rapid build-up of fat mass may lead to metabolic
syndrome [8]. Also, TB patients often experience
inflammation-induced anaemia as a consequence of the
TB disease [9], thus a rise in haemoglobin during TB
treatment can be considered a marker of recovery. We
recently reported from Tanzania that while diabetes was
associated with a higher risk of TB [10], diabetes had lit-
tle consequences for the clinical manifestations of newly
diagnosed TB [11]. In this paper we report the changes
in anthropometry, grip strength, and clinical parameters
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over a five months follow-up period, to assess the role of
diabetes on recovery during TB treatment.
Methods
Study population and design
From 2006 to 2008 patients newly diagnosed with active
pulmonary TB were consecutively enrolled in this pro-
spective cohort study in the framework of two large ran-
domized, double-blind, controlled nutrition intervention
studies, with all patients diagnosed and treated for TB
according to international guidelines [12]. All partici-
pants were randomized to either an energy-protein study
[13] or a multi-micronutrient study [14] comparing the
effect of high-doses against low-doses. To be eligible for
the energy-protein study, TB patients had to be diag-
nosed as sputum positive pulmonary TB (PTB+) with
HIV co-infection. All other enrolled TB patients were
eligible for the multi-micronutrient study.
The study was conducted in an urban setting in
Mwanza City, northern Tanzania. Tanzania ranks among
the world’s 22 high TB-burden countries [15], with a low
prevalence of multi-drug resistant TB [16], and half of
the TB patients co-infected with HIV [17]. The esti-
mated national diabetes prevalence in 2011 in Tanzania
was 2.3% [18]. All participants underwent baseline
examination of anthropometry, diabetes, and HIV, and
venous blood samples were drawn for additional labora-
tory analyses. To be included in the study testing for
HIV was mandatory. Persons below fifteen years of age,
pregnant or lactating women, terminally ill, and non-
residents of Mwanza City were all excluded.
Measurements
Sputum results were done as part of the routine diag-
nostic procedure using “spot-morning-spot” samples
(method described in [12]) using Ziehl-Nielsen staining
technique in combination with culture of Mycobacter-
ium tuberculosis on Lowenstein Jensen solid media. All
participants had verified pulmonary TB (PTB); in this
study a positive culture test result was defined as PTB+
with the diagnosis relying primarily on culture status;
initial microscopy results were only used if the culture
result was missing. In case of a negative culture result,
the diagnosis was defined as sputum negative pulmonary
TB (PTB-), in which case the TB diagnosis was based on
clinical suspicion, history of disease, lack of clinical im-
provement after treatment with a broad antibiotic
spectrum as well as a positive x-ray result as suggested
by WHO [19].
Weight (Seca, Hamburg, Germany) and height were
measured with the participant barefoot and with min-
imal clothing (nearest 0.1 kg and 0.1 cm), from which
body mass index (BMI) was calculated as weight/height2
(kg/m2). Waist circumference was measured between
the lower costae and the iliac crest. The midpoint be-
tween the acromion process of the shoulder and olecra-
non process of the ulna bone was determined and
marked on the left arm, on which mark the triceps
skinfold thickness (TST) (Harpenden caliper, Baty Inter-
national, West Sussex, UK) was measured (with arm
hanging loosely). Mid-upper arm circumference
(MUAC) was measured on the same arm and same
mark using a standard tape, but with the arm flexed in
a 90° angle. Measuring TST and MUAC allowed for es-
timation of arm fat area and arm muscle area (methods
for calculation described in [20]). Finally, grip strength
(0.1 kg) was assessed using a digital hand dynamometer
(Takei Scientific Instruments, Niigata City, Japan). All
anthropometric measurements were performed in
duplicate.
Fasting blood glucose (FBG) was determined on capil-
lary whole blood using point-of-care diagnostic instru-
ments (HemoCue Glucose System, Ängelholm, Sweden).
The test was performed between 8.00-10.00 AM after an
overnight fasting period (> 8 hours), and only water was
allowed prior to the test. As the FBG in the TB partici-
pants might be affected by the infection (non-diabetes
stress hyperglycaemia) [21,22], the range of the FBG for
offering a standard two hour (2 h) oral glucose tolerance
test (OGTT) was expanded from the commonly used
5.6-6.0 mmol/L; those with a FBG between 5.1-
11.0 mmol/L completed the 2 h OGTT (intake of 75 g
of anhydrous glucose dissolved in water), whereas those
with FBG< 5.1 or >11.0 mmol/L did not. Final diabetes
diagnosis was based on either a FBG> 6.0 mmol/L or a
2 h blood glucose >11.0 mmol/L [23]. Since the diagno-
sis of diabetes was for epidemiological purposes only, we
did not repeat the test in those with values suggestive of
diabetes. Participants diagnosed with diabetes prior to
their TB diagnosis were only classified as such, if the
diabetes diagnosis was reproduced within the present
study. The diabetes testing was performed as soon as
possible after initiation of TB treatment to eliminate the
role of adverse drug effects.
Venous blood was drawn in EDTA tubes at local
health facilities and transported to the research labora-
tory, whereupon serum was collected and kept at −80 °C
until analysed. HIV diagnosis was based on two rapid
tests, Determine HIV 1/2 (Inverness Medical Innova-
tions Inc., Delaware, USA) and Capillus HIV-1/HIV-2
(Trinity Biotech Plc., Wicklow, Ireland). If the HIV test
results were discordant, ELISA was used. Cluster of dif-
ferentiation 4 (CD4) counts were determined by flow
cytometry after CD4 immuno-flourochrome staining of
the leucocytes (Partec FACS, Partec GmbH., Germany),
and haemoglobin levels (g/dL) and white blood cell
(109/L) counts, including differentials, were carried out
at the research laboratory at the National Institute for
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Medical Research in Mwanza. Serum concentrations (g/L)
of the acute phase reactant alpha-1-acid glycoprotein were
determined at the Department of Clinical Biochemistry,
Aalborg University Hospital, Denmark.
Information using standardized questionnaires on
demographic information, smoking habits, and alcohol
intake was collected. Smokers were grouped as either
previous or current smokers, and alcohol intake was
classified as either no intake or any intake.
Follow-up visits at two and five months
All anthropometric measurements, grip strength and the
biological measurements (haemoglobin, white blood
cells, CD4) were repeated at the two and five months
visit. The diabetes and HIV testing were not repeated,
thus the baseline diagnosis was used throughout the
study period.
Statistical analysis
Data were double entered, and all statistical analyses
were performed using Stata 12.0 (StataCorp LP, College
Station, USA). The distribution of continuous variables
was assessed for normality. The t-test was used to test
for differences in means and the Χ2-test was used to test
for differences in proportions across diabetes status. A
linear mixed-effects model [24] was used to assess the
changes across diabetes status for anthropometry, grip
strength and biological measurements at baseline as well
as after two and five months of TB treatment (repeated
measurements). The mixed-effects models were adjusted
for baseline age, sex, HIV status, alpha-1 glycoprotein,
smoking habits, alcohol intake, and nutritional
intervention.
Ethical considerations
Ethical permission was obtained from the Medical Re-
search Coordinating committee of the National Institute
for Medical Research (NIMR) in Tanzania, and consulta-
tive approval was given by The Danish National Com-
mittee on Biomedical Research Ethics. Written and oral
information was presented to all eligible participants by
the health staff before written informed consent was
obtained. Written consent was obtained from parents/
legal guardians of any participants under 18 years of age.
Counselling prior to HIV-testing was compulsory, and
post-test counselling was offered to all who tested HIV-
positive. Participants with diagnosed HIV and/or dia-
betes were referred for follow-up at the respective clinics
for care and management.
Results
Diabetes data were available for 1205 (96.4%) of the
1250 patients enrolled and included in the analyses. Of
the 1205 TB patients 197 (16.3%) were categorized as
having diabetes, which has previously been reported for
PTB+ patients only (n = 803) [10]. The mean (standard
deviation) age was 36.6 (13.0) years, 40.9% were females,
and 48.9% were HIV co-infected. There were no differ-
ences in background characteristics between TB patients
with and without diabetes (Table 1).
The changes in anthropometric measurements during
TB treatment are shown in table 2. Within the initial
two months of TB treatment, TB patients with diabetes
co-morbidity experienced a 1.3 kg (CI 95% 0.5; 2.0,
p = 0.001) lower weight gain compared to the non-
diabetes group. The delayed weight gain sustained at five
months of TB treatment, with a 1.0 kg (CI 95% 0.3; 1.7,
Table 1 Background characteristics of 1205 pulmonary
tuberculosis patients with (n = 197) or without
(n =1008) diabetes
Patients without
diabetes
Patients with
diabetes
p
(n = 1008) (n = 197)
Age, years (mean [SD]) 36.3 [12.8] 38.0 [13.6] 0.083
Female sex 404 (40.1) 89 (45.2) 0.183
HIV infection 507 (50.3) 97 (49.2) 0.786
TB status
PTB- 339 (33.6) 63 (32.0) 0.65
PTB+ 669 (66.4) 134 (68.0)
Ethnic group
Msukuma tribe 459 (45.6) 94 (47.7) 0.582
Other tribes 548 (54.4) 103 (52.3)
Marital status
Single 249 (24.9) 42 (21.5) 0.605
Married/cohabiting 528 (52.8) 108 (55.4)
Separated/divorced/widow 223 (22.3) 45 (23.1)
Occupation
Farmer/Fisherman 394 (39.2) 75 (38.3) 0.974
Businessman/Employed 356 (35.4) 74 (37.8)
Housewife 120 (11.9) 23 (11.7)
Unemployed 51 (5.1) 9 (4.6)
Religion
Christian 741 (73.6) 155 (78.7) 0.191
Muslim 223 (22.1) 38 (19.3)
Smoking
Never 675 (82.9) 139 (17.1) 0.60
Past smoker 110 (85.9) 18 (14.1)
Current smoker 216 (84.7) 39 (15.3)
Take alcohol
No 533 (82.9) 110 (17.1) 0.45
Yes 475 (84.5) 87 (15.5)
Data are n(%) unless otherwise specified.
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p = 0.007) lower weight gain among TB patients with
diabetes co-morbidity (Table 2, Figure 1a). There was no
baseline difference in the mean MUAC (22.9 vs.
23.3 cm, p = 0.185) and TST (7.2 vs. 7.3, p = 0.581) be-
tween those with and without diabetes. However, the in-
crease in MUAC was higher in the non-diabetes group
after two (Δ 0.3 g/dL, CI 95% 0.04; 0.6 p = 0.027) and
five months (Δ 0.3 g/dL, CI 95% 0.02; 0.6 p = 0.036),
whereas no difference was found for TST (two months:
Δ 0.3 g/dL, CI 95% -0.2; 0.8 p = 0.288 and five months: Δ
0.3 g/dL, CI 95% -0.2; 0.8 p = 0.283). Although signifi-
cant increases were seen for arm muscle area and arm
fat area for both groups, there were no differences across
diabetes status. Similarly, there were significant increases
for waist circumference and grip strength, but the in-
crease seemed to be unaffected by diabetes status.
The mean haemoglobin level was 10.7 g/dL at base-
line, and was similar for non-diabetes and diabetes parti-
cipants (Δ 0.03 g/dL, p = 0.851). However, the increase
in haemoglobin was 0.6 g/dL (CI 95% 0.3; 0.9 p< 0.001)
and 0.5 g/dL (CI 95% 0.2; 0.9 p = 0.004) lower after two
and five months, respectively, among TB patients with
diabetes co-morbidity (Table 3, Figure 1b). Diabetes did
not affect the changes in the level of white blood cells
and CD4 counts, and this was not modified by HIV sta-
tus (data not shown).
Discussion
Diabetes co-morbidity was associated with delayed re-
covery of weight and haemoglobin level within the first
two months of TB treatment, and the accumulated dif-
ference persisted after five months. However, the func-
tional recovery based on grip strength assessment was
not affected by diabetes.
Being enrolled in a nutritional intervention study
ensured that all participants had access to some
Table 2 Changes in anthropometric measurements and
grip strength during TB treatment among TB patients
with (n = 197) or without (n =1008) diabetes
Patients without
diabetes
Patients with
diabetes
(n = 2008) (n = 197)
Mean (95% CI) Mean (95% CI) P
Weight, kg
Baseline 51.8 (51.3; 52.3) 53.3 (52.1; 54.5)
2 months 54.8 (54.3; 55.3) 55.1 (53.9; 56.3)
Increase 3.0 (2.7; 3.3) 1.7 (1.1; 2.4)
Difference 1.3 (0.5; 2.0) 0.001
5 months 57.1 (56.6; 57.7) 57.7 (56.4; 58.9)
Increase 5.3 (5.0; 5.6) 4.3 (3.7; 5.0)
Difference 1.0 (0.3; 1.7) 0.007
BMI, kg/m2
Baseline 18.7 (18.6; 18.9) 19.3 (18.9; 19.7)
2 months 19.8 (19.6; 20.0) 19.9 (19.5; 20.3)
Increase 1.1 (1.0; 1.2) 0.6 (0.4; 0.9)
Difference 0.4 (0.2; 0.7) 0.001
5 months 20.7 (20.5; 20.9) 20.9 (20.4; 21.3)
Increase 1.9 (1.8; 2.0) 1.6 (1.3; 1.8)
Difference 0.3 (0.1; 0.6) 0.012
Waist circumference, cm
Baseline 72.1 (71.7; 72.5) 73.7 (72.8; 74.7)
2 months 74.5 (74.0; 74.9) 75.8 (74.8; 76.9)
Increase 2.4 (2.1; 2.7) 2.1 (1.4; 2.8)
Difference 0.3 (−0.5; 1.0) 0.512
5 months 76.3 (75.9; 76.8) 77.8 (76.8; 78.8)
Increase 4.2 (3.9; 4.5) 4.1 (3.3; 4.8)
Difference 0.2 (−0.6; 1.0) 0.697
AMA, mm2
Baseline 34.6 (34.0; 35.1) 35.6 (34.3; 37.0)
2 months 37.2 (36.6; 37.8) 37.4 (36.0; 38.7)
Increase 2.7 (2.2; 3.1) 1.7 (0.7; 2.7)
Difference 0.9 (−0.2; 2.0) 0.100
5 months 40.7 (40.1; 41.4) 41.0 (39.6; 42.4)
Increase 6.2 (5.7; 6.6) 5.4 (4.4; 6.4)
Difference 0.8 (−0.3; 1.9) 0.164
AFA, mm2
Baseline 8.1 (7.8; 8.4) 8.3 (7.6; 9.0)
2 months 9.2 (8.9; 9.5) 9.0 (8.3; 9.8)
Increase 1.1 (0.9; 1.4) 0.8 (0.1; 1.4)
Difference 0.4 (−0.3; 1.0) 0.297
5 months 10.4 (10.1; 10.8) 10.4 (9.6; 11.2)
Increase 2.3 (2.1; 2.6) 2.1 (1.5; 2.8)
Difference 0.2 (−0.5; 0.9) 0.524
Table 2 Changes in anthropometric measurements and
grip strength during TB treatment among TB patients
with (n = 197) or without (n =1008) diabetes (Continued)
Grip strength, kg
Baseline 25.8 (25.3; 26.3) 25.2 (24.2; 26.2)
2 months 27.6 (27.2; 28.1) 26.8 (25.7; 27.9)
Increase 1.8 (1.5; 2,2) 1.6 (0.7; 2.4)
Difference 0.2 (−0.7; 1.2) 0.610
5 months 30.5 (30.0; 30.9) 29.6 (28.5; 30.7)
Increase 4.7 (4.3; 5.0) 4.4 (3.5; 5.2)
Difference 0.3 (−0.7; 1.2) 0.550
Data are mean (95% confidence interval) based on multilevel mixed-effects
linear regression, adjusted for age, sex, HIV status, alpha-1 glycoprotein,
smoking habits, alcohol intake, and nutritional intervention.
TB: pulmonary tuberculosis, BMI: body mass index, AMA: arm muscle area,
AFA: arm fat area.
Faurholt-Jepsen et al. BMC Infectious Diseases 2012, 12:165 Page 4 of 8
http://www.biomedcentral.com/1471-2334/12/165
nutritional support during the first two months of TB
treatment. We recently reported that smear-positive TB
was associated with a 10 kg weight loss, which was both
reflected in large deficits in arm fat area and especially
arm muscle area [7], suggesting that nutritional support
to facilitate optimal recovery of lean body mass is
needed during the treatment. As reported here, there
was a considerable delayed weight gain in those with
diabetes. On average the participants gained three and
five kg over the two and five months treatment period,
respectively, but participants with diabetes had a one kg
weight deficit compared to the non-diabetes patients at
both time points. Interestingly, this weight difference
was built up during the first two months, and sustained
at the same level after five months. Also MUAC
increased at a slower pace in the diabetes group, whereas
TST did not. That MUAC and TST did not behave simi-
larly was reflected in the derived parameter arm muscle
area, which also seemed to be increasing slower in the
diabetes group. This could imply that people with dia-
betes have a slower muscle build-up, but this was not
backed up by the functional measurement grip strength.
The low levels of haemoglobin at baseline are primar-
ily inflammation-induced anaemia from the on-going
HIV and TB infections [9,25]. Regardless of the under-
lying cause, the haemoglobin level is expected to rise
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Figure 1 a Changes in weight level during treatment among pulmonary tuberculosis patients with (n = 197) or without (n = 1008)
diabetes. Figure 1b. Changes in haemoglobin level during treatment among pulmonary tuberculosis patients with (n = 197) or without (n = 1008)
diabetes.
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during recovery, which we also found with reasonable
increases at two and five months. The slower increase in
haemoglobin in those with diabetes could be the conse-
quence of sooner improvement in the non-diabetes
group. In parallel with the replenishment of iron to
haemoglobin, there may also be a direct association be-
tween haemoglobin and lean body mass; either caused
by mutual factors improving both lean body mass and
haemoglobin levels, or local hypoxia due to low haemo-
globin may be the delimiting factor in the build-up of
lean body mass in the diabetes group.
The differences we found did not depend on TB sta-
tus, since the diabetes-associated differences were
present among both PTB+ and PTB- participants. As
suggested, the delayed increase in weight gain and
haemoglobin levels in the diabetes group could partly be
explained by a slower TB recovery. From a study in se-
verely acute malnourished (marasmic) adults it has been
shown that the daily increase in body weight during re-
plenishment is app. 6 g per kg body weight [26]. Thus,
any delay in TB recovery may interfere with body mass
recovery. However, the slower improvement observed in
our study could also be a consequence of poorly con-
trolled diabetes, which is known to be associated with
protein degradation and leucine oxidation [27,28].
Finally, the association between diabetes and slow recov-
ery could be explained by reverse causality; i.e. those
with slower recovery may have more severe TB
disease, and this could give rise to non-diabetes stress-
hyperglycaemia [21,22], which may have been misclassi-
fied as diabetes. However, this is not likely to be a major
factor in this study, since we have observed very little,
and probably not clinically important, baseline differ-
ences in the acute phase response between diabetes and
non-diabetes participants [11], indicating similar base-
line severity of TB in the two groups, and, furthermore,
since the differences observed were not confounded by
the acute phase response. We have previously reported
fluctuations in the CD4 level during TB treatment with
increases over the initial two months of treatment and
with a subsequent decrease [29]. However, the data from
this study show that the fluctuations were not affected
by diabetes co-morbidity.
All patients diagnosed with diabetes were referred to
the local diabetes clinics to be retested and treated ac-
cordingly. Data on anti-diabetic treatment has not been
available for the present study, however, patients with a
reconfirmation of diabetes have most likely started out
with advice on lifestyle changes, and therefore medical
intervention is unlikely to be confounding the data.
Conclusion
TB patients initiating TB treatment with diabetes co-
morbidity may experience slower recovery from their
Table 3 Changes in haemoglobin level, white blood cell
and CD4 count during treatment among pulmonary
tuberculosis patients with (n = 197) or without (n =1008)
diabetes
Patients without
diabetes
Patients with
diabetes
(n =2008) (n = 197)
Mean (95% CI) Mean (95% CI) P
Haemoglobin, g pr. dL
Baseline 10.8 (10.6; 10.9) 10.7 (10.4; 11.0)
2 months 12.3 (12.2; 12.5) 11.7 (11.4; 12.0)
Increase 1.6 (1.4; 1.7) 1.0 (0.7; 1.3)
Difference 0.6 (0.3; 0.9) < 0.001
5 months 13.0 (12.8; 13.1) 12.4 (12.1; 12.7)
Increase 2.2 (2.1; 2.3) 1.7 (1.4; 2.0)
Difference 0.5 (0.2; 0.9) 0.004
White blood cell
count (total), 109
cells pr. L
Baseline 6.4 (6.3; 6.6) 6.8 (6.5; 7.1)
2 months 4.7 (4.6; 4.8) 5.0 (4.7; 5.3)
Increase −1.7 (−1.9; -1.6) −1.7 (−2.1; -1.4)
Difference 0.02 (−0.3; 0.4) 0.918
5 months 4.3 (4.1; 4.4) 4.6 (4.3; 4.9)
Increase −2.2 (−2.3; -2.0) −2.2 (−2.5; -1.8)
Difference −0.03 (−0.4; 0.3) 0.889
Neutrophil
granulocytes,
109 cells pr. L
Baseline 4.1 (4.0; 4.2) 4.6 (4.4; 4.8)
2 months 2.3 (2.2; 2.4) 2.6 (2.4; 2.8)
Increase −1.8 (−2.0; -1.7) −2.0 (−2.2; -1.7)
Difference 0.1 (−0.2; 0.4) 0.493
5 months 1.8 (1.7; 2.0) 2.2 (2.0; 2.5)
Increase −2.3 (−2.4; -2.1) −2.3 (−2.6; -2.1)
Difference 0.1 (−0.2; 0.4) 0.658
CD4 count,
cells pr. μL
Baseline 425.9 (408.9; 442.8) 409.2 (370.6; 447.8)
2 months 477.5 (459.9; 495.2) 435.1 (393.7; 476.5)
Increase 51.7 (29.7; 73.6) 25.9 (−25.0; 76.8)
Difference 25.7 (−29.7; 81.2) 0.362
5 months 436.2 (417.7; 454.6) 396.6 (353.7; 439.6)
Increase 10.3 (−12.3; 32.9) −12.5 (−64.6; 39.6)
Difference 22.8 (−33.9; 79.6) 0.431
Data are mean (95% confidence interval) based on a linear mixed-effects
model, adjusted for age, sex, HIV status, alpha-1 glycoprotein, smoking habits,
alcohol intake, and nutritional intervention.
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TB disease. While previous studies have primarily fo-
cused on treatment outcomes related to the TB cul-
ture (or smear) intensity, conversion, cure and
mortality, this study looked at general outcomes,
such as anthropometry and haemoglobin, which are
important for the functional recovery. A quick func-
tional recovery leads to a sooner return to work, and
thus, the delay may not only have beneficial health
outcomes, but also economically consequences for
low-income families burdened by TB.
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